Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retatrutide Response to Hypoglycemia in Type 2 Diabetes Mellitus
NCT06982846Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2025
- Primary completion
- May 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in type 2 diabetes mellitus (T2DM) comparing Retatrutide with Placebo (2 arms). Primary endpoint: Time-to-Event of Recovery of Plasma Glucose (PG) Concentration from 48 mg/dL to 70 mg/dL. Started Jun 2025; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06982846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06982846.